摘要
目的 :建立抗SARS冠状病毒 (SARS_CoV)药物细胞筛选模型 ,应用于抗SARS_CoV药物的筛选 ,为SARS的防治奠定基础。方法 :将一定数量的细胞接种 96孔板 ,根据药物的作用机制采用不同的给药途径 ,以观察到的细胞病变 (cytopathiceffect,CPE)为指标 ,按照Reed_Muench法 ,计算药物的细胞半数中毒浓度 (TD50 )和抑制细胞半数病变的有效浓度 (IC50 )。结果与结论 :Vero_E6细胞接种SARS_CoV后 2 4h即可出现CPE ,且CPE明显 ,便于观察 ,可作为抗SARS病毒药物细胞筛选模型。依此模型筛选了 3类 87种药物 ,确认 6种药物在Vero_E6细胞上具有抑制SARS病毒的作用。该模型的建立也为其他的抗病毒药物的筛选提供了技术平台。
Objective:To establish cell screening model for anti-SARS-CoV drugs, this model was used to screen drugs for anti-SARS-CoV. The results can provide theory basis for treatment and prevention of SARS in clinical work.Methods:A certain amount of cells were cultured in 96-wells cell culture plate. The different dilutions of the drug were inoculated to monolayer of Vero-E6 with different methods and the cytopathic effect (CPE) was observed. The TD 50 and IC 50 of the drug were calculated by the method of Reed-Muench. Results and Conclusion:SARS-CoVs were inoculated in Vero-E6 cells. After 24?h,significant CPE was observed and was easy to be found. So Vero-E6 cell was fit to become a screening model for anti-SARS-CoV drugs. Eighty-seven drugs were screened by this model. The results indicated that six of the drugs might inhibit SARS-CoV replication in Vero-E6 cells.
出处
《军事医学科学院院刊》
CSCD
北大核心
2003年第5期325-326,369,共3页
Bulletin of the Academy of Military Medical Sciences
